Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on June 11, 2026 to stockholders who are on record at the close of business on May 29, 2026.
The company highlights its global scale, noting nearly 71,000 employees serving clients in about 100 countries and performing more than 750 million tests annually, as well as providing support for 85% of new drugs and therapeutic products approved by the FDA in 2025.
Labcorp Holdings Inc. will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026, and will host a conference call and webcast at 9:00 a.m. ET to discuss the results.
The earnings press release and financial information will be posted on the Labcorp Investor Relations website, where a link to the webcast and a replay available for one year will also be provided. Labcorp is described as a global leader in laboratory services, with nearly 71,000 employees serving clients in about 100 countries.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter received a grant of 58,470 shares of Common Stock on March 26, 2026, as a performance award tied to results for the three-year period ended December 31, 2025. To cover related tax obligations, 26,106 shares of Common Stock were withheld at $268.38 per share rather than sold in the open market. After these compensation and tax-withholding entries, Schechter directly holds 113,137 shares of Common Stock.
LABCORP HOLDINGS INC. executive Anita Z. Graham, EVP and CHRO, received 6,604 shares of common stock on March 26, 2026 as a performance-based equity award. The award relates to performance over the three-year period ended December 31, 2025 from a grant made on April 5, 2023.
To cover tax withholding obligations, 2,879 shares were automatically withheld at $268.38 per share, which is recorded as a disposition but is not an open-market sale. After these transactions, Graham directly holds 5,185 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Mark S. Schroeder, EVP and President of Diagnostics & COO, reported equity compensation activity in the company’s common stock. On March 26, 2026, he acquired 9,304 shares pursuant to a performance award granted on February 7, 2023 and 2,968 shares pursuant to a performance award granted on May 5, 2023, both tied to performance for the three-year period ended December 31, 2025. To cover tax withholding obligations, 4,600 shares and 1,468 shares were withheld at a price of $268.38 per share. Following these grant and tax-withholding transactions, he directly held 12,677.1426 shares of common stock.
LABCORP HOLDINGS INC. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, CMO & CSO, reported stock-based compensation and related tax withholding. On March 26, 2026, he acquired 9,304 and 1,986 shares of common stock from performance awards tied to the three-year period ended December 31, 2025. To satisfy tax withholding obligations, 4,042 and 863 shares were withheld at $268.38 per share. After these transactions, he directly owned 36,491.9234 shares of Labcorp common stock.
Labcorp Holdings senior vice president and chief accounting officer Peter J. Wilkinson reported a mix of equity compensation and related share dispositions. On March 26, 2026, he acquired 2,388 shares of common stock at $0.00 per share pursuant to a performance award covering the three-year period ended December 31, 2025. That same day, 755 shares were withheld at $268.38 per share to satisfy tax withholding obligations, leaving 3,485.2194 shares directly owned. On March 27, 2026, he executed an open-market sale of 1,633 shares at an average price of $267.05 per share under a pre-arranged Rule 10b5-1 trading plan, resulting in direct ownership of 1,852.2194 shares.
LABCORP HOLDINGS INC. executive EVP, Diagnostics Bryan T. Vaughn received 1,584 shares of common stock on March 26, 2026 as a performance award tied to results over the three-year period ended December 31, 2025. To cover tax obligations, 451 shares were withheld at $268.38 per share, leaving him with 6,745.5702 directly owned shares after these transactions.
LABCORP HOLDINGS INC. executive Sandra D. van der Vaart, EVP, Corporate Affairs, received a grant of 6,382 shares of common stock on March 26, 2026. The award was earned under a performance plan covering the three-year period ended December 31, 2025.
To cover tax withholding obligations on this award, 2,722 shares were withheld at a price of $268.38 per share, rather than sold in the open market. After these transactions, she directly holds 6,238.9467 shares of Labcorp common stock.
LABCORP HOLDINGS INC. executive Amy B. Summy received 3,994 shares of common stock on March 26, 2026, as a performance award tied to the three-year period ended December 31, 2025. To cover tax obligations, 1,836 shares were withheld at $268.38 per share, leaving her with 7,879.5 shares held directly after these transactions.